How does BHM's PE Ratio compare to its peers?

BHM is expensive based on its Price-To-Earnings Ratio (40.4x) compared to the peer average (21x).

How does BHM's PE Ratio compare vs other companies in the European Life Sciences Industry?

BHM is expensive based on its Price-To-Earnings Ratio (40.4x) compared to the European Life Sciences industry average (38.2x).

What is BHM's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BHM is expensive based on its Price-To-Earnings Ratio (40.4x) compared to the estimated Fair Price-To-Earnings Ratio (19.5x).

What is the Fair Price of BHM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

BHM (€6.35) is trading above our estimate of [[fair value]] (€2.61)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

BHM Stock Overview

Provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. More details

BHM fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	5/6
Financial Health	6/6
Dividends	3/6

Rewards

Earnings are forecast to grow 17.92% per year

Earnings grew by 15.3% over the past year

Risk Analysis

Volatile share price over the past 3 months compared to the German market

My Notes

Capture your thoughts, links and company narrative

Bachem Holding AG Competitors

SCHOTT Pharma KGaA

XTRA:1SXP

€3.6b

Gerresheimer

XTRA:GXI

€2.5b

Dermapharm Holding

XTRA:DMP

€2.0b

Biotest

XTRA:BIO3

€1.3b

Price History & Performance

Summary of share price highs, lows and changes for Bachem Holding
Historical stock prices
Current Share Price	CHF 6.35
52 Week High	CHF 9.90
52 Week Low	CHF 5.04
Beta	0.72
1 Month Change	-7.30%
3 Month Change	-13.01%
1 Year Change	-14.99%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-20.96%

Recent updates

Shareholder Returns

	BHM	DE Life Sciences	DE Market
7D	-4.5%	-4.2%	-2.6%
1Y	-15.0%	-5.3%	7.1%

Return vs Industry: BHM underperformed the German Life Sciences industry which returned -3.9% over the past year.

Return vs Market: BHM underperformed the German Market which returned 8% over the past year.

Price Volatility

Is BHM's price volatile compared to industry and market?
BHM volatility
BHM Average Weekly Movement	7.6%
Life Sciences Industry Average Movement	7.2%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	11.6%
10% least volatile stocks in DE Market	2.5%

Stable Share Price: BHM's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: BHM's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
1971	2,009	Thomas Meier	www.bachem.com

Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. The company engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). It also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services.

Bachem Holding AG Fundamentals Summary

How do Bachem Holding's earnings and revenue compare to its market cap?
BHM fundamental statistics
Market cap	€4.92b
Earnings (TTM)	€121.97m
Revenue (TTM)	€620.53m

40.4x

P/E Ratio

7.9x

P/S Ratio

Is BHM overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BHM income statement (TTM)
Revenue	CHF 577.77m
Cost of Revenue	CHF 398.41m
Gross Profit	CHF 179.36m
Other Expenses	CHF 65.79m
Earnings	CHF 113.57m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Feb 27, 2025

Earnings per share (EPS)	1.51
Gross Margin	31.04%
Net Profit Margin	19.66%
Debt/Equity Ratio	0%

How did BHM perform over the long term?

See historical performance and comparison

Dividends

1.3%

Current Dividend Yield

53%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/19 15:15
End of Day Share Price	2024/12/19 00:00
Earnings	2024/06/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Bachem Holding AG is covered by 23 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Konstantin Wiechert	Baader Helvea Equity Research
Volker Bosse	Baader Helvea Equity Research
Markus Mayer	Baader Helvea Equity Research

Bachem Holding DB:BHM Stock Report